AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.

Animals HIV Infections Simian Acquired Immunodeficiency Syndrome Simian Immunodeficiency Virus / physiology Macaca mulatta Anti-Retroviral Agents / pharmacology Virus Latency Virus Replication HIV-1 Antibodies / therapeutic use Lymph Nodes CD4-Positive T-Lymphocytes Viral Load

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
10 2023
Historique:
received: 12 12 2022
accepted: 25 08 2023
medline: 23 10 2023
pubmed: 3 10 2023
entrez: 2 10 2023
Statut: ppublish

Résumé

The main barrier to HIV cure is a persistent reservoir of latently infected CD4

Identifiants

DOI: 10.1038/s41591-023-02570-7 PMID: 37783968 PMC: PMC10579098
pubmed: 37783968
doi: 10.1038/s41591-023-02570-7
pii: 10.1038/s41591-023-02570-7
pmc: PMC10579098
doi:

Substances chimiques

N,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide) 0
Anti-Retroviral Agents 0
Antibodies 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2535-2546

Subventions

Organisme : NHLBI NIH HHS
ID : U54 HL143541
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126619
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI124436
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI028433
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI164567
Pays : United States
Organisme : NIH HHS
ID : R01 OD011095
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI169662
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI157862
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI162242
Pays : United States
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152703
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI046518
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
pubmed: 9360927 doi: 10.1126/science.278.5341.1295
Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
pubmed: 9360926 doi: 10.1126/science.278.5341.1291
Chun, T. W. et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24, 2803–2808 (2010).
pubmed: 20962613 doi: 10.1097/QAD.0b013e328340a239
Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat. Med. 27, 2085–2098 (2021).
pubmed: 34848888 doi: 10.1038/s41591-021-01590-5
Lee, M. J. et al. Immunotherapeutic approaches to HIV cure and remission. Curr. Op. Infect. Dis. 35, 31–41 (2022).
doi: 10.1097/QCO.0000000000000803
Mavigner, M. & Chahroudi, A. Broadly neutralizing antibodies: "The next thing" to treat children with HIV? Sci. Trans. Med. 15, eadi0293 (2023).
Landovitz, R. J. et al. Prevention, treatment and cure of HIV infection. Nat. Rev. Micro. 21, 657–670 (2023).
doi: 10.1038/s41579-023-00914-1
Archin, N. M. et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J. Clin. Invest. 127, 3126–3135 (2017).
pubmed: 28714868 pmcid: 5531421 doi: 10.1172/JCI92684
Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
pubmed: 22837004 pmcid: 3704185 doi: 10.1038/nature11286
Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2, e520–e529 (2015).
pubmed: 26614966 pmcid: 5108570 doi: 10.1016/S2352-3018(15)00226-X
Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).
pubmed: 25393648 pmcid: 4231123 doi: 10.1371/journal.ppat.1004473
Gutierrez, C. et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 30, 1385–1392 (2016).
pubmed: 26891037 doi: 10.1097/QAD.0000000000001064
Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21 (2014).
pubmed: 26423811 doi: 10.1016/S2352-3018(14)70014-1
Sogaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).
pubmed: 26379282 pmcid: 4575032 doi: 10.1371/journal.ppat.1005142
Kim, Y. et al. Getting the “Kill" into “Shock and Kill: Strategies to Eliminate Latent HIV. Cell Host & Microbe 23, 14–26 (2018).
doi: 10.1016/j.chom.2017.12.004
Nixon, C. C. et al. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature 578, 160–165 (2020).
pubmed: 31969707 pmcid: 7111210 doi: 10.1038/s41586-020-1951-3
McBrien, J. B. et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8
pubmed: 31969705 pmcid: 7580846 doi: 10.1038/s41586-020-1946-0
Dashti, A. et al. SMAC mimetic plus triple-combination bispecific HIV×CD3 retargeting molecules in SHIV.C.CH505-infected, antiretroviral therapy-suppressed rhesus macaques. J. Virol. 94, e00793–20 (2020).
pubmed: 32817214 pmcid: 7565632 doi: 10.1128/JVI.00793-20
Welles, H. C. et al. Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. PLoS Pathog. 18, e1010574 (2022).
pubmed: 35709309 pmcid: 9242510 doi: 10.1371/journal.ppat.1010574
Grunst, M. W. et al. Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein. PLoS Pathog. 19, e1011407 (2023).
pubmed: 37253062 pmcid: 10256149 doi: 10.1371/journal.ppat.1011407
Harwood, O. & O’Connor, S. Therapeutic potential of IL-15 and N-803 in HIV/SIV infection. Viruses 13, 1750 (2021).
pubmed: 34578331 pmcid: 8473246 doi: 10.3390/v13091750
Jones, R. B. et al. A subset of latency-reversing agents expose HIV-infected resting CD4
pubmed: 27082643 pmcid: 4833318 doi: 10.1371/journal.ppat.1005545
Mason, R. D. et al. Targeted isolation of antibodies directed against major sites of SIV Env vulnerability. PLoS Pathog. 12, e1005537 (2016).
pubmed: 27064278 pmcid: 4827850 doi: 10.1371/journal.ppat.1005537
Banga, R., Munoz, O. & Perreau, M. HIV persistence in lymph nodes. Curr. Opin. HIV AIDS 16, 209–214 (2021).
pubmed: 34059608 doi: 10.1097/COH.0000000000000686
Pollara, J. et al. Functional homology for antibody-dependent phagocytosis across humans and rhesus macaques. Front. Immunol. 12, 678511 (2021).
pubmed: 34093580 pmcid: 8174565 doi: 10.3389/fimmu.2021.678511
Jenkins, M., Mills, J. & Kohl, S. Natural killer cytotoxicity and antibody-dependent cellular cytotoxicity of human immunodeficiency virus–infected cells by leukocytes from human neonates and adults. Pediatr. Res. 33, 469–474 (1993).
pubmed: 8511019 doi: 10.1203/00006450-199305000-00010
Karsten, C. B. et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J. Immunol. Methods 471, 46–56 (2019).
pubmed: 31132351 pmcid: 6620195 doi: 10.1016/j.jim.2019.05.006
Bruel, T. et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 7, 10844 (2016).
pubmed: 26936020 pmcid: 4782064 doi: 10.1038/ncomms10844
Huang, S.-H. et al. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J. Clin. Invest. 128, 876–889 (2018).
pubmed: 29355843 pmcid: 5785246 doi: 10.1172/JCI97555
Dai, W. et al. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir. Sci. Trans. Med. 14, eabh335 (2022).
doi: 10.1126/scitranslmed.abh3351
Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).
pubmed: 26702094 doi: 10.1126/scitranslmed.aad5752
Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224–228 (2013).
pubmed: 24172905 pmcid: 4017780 doi: 10.1038/nature12744
Mavigner, M. et al. CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques. J. Virol. 95, e01429-20 (2021).
Pollack, R. A. et al. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape. Cell Host Microbe 21, 494–506 (2017).
pubmed: 28407485 pmcid: 5433942 doi: 10.1016/j.chom.2017.03.008
Miller, J. S. et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat. Med. 28, 392–400 (2022).
pubmed: 35102335 doi: 10.1038/s41591-021-01651-9
Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360–364 (2018).
pubmed: 30283138 pmcid: 6237629 doi: 10.1038/s41586-018-0600-6
Moldt, B. et al. HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. PLoS Pathog. 18, e1010467 (2022).
pubmed: 35452496 pmcid: 9067686 doi: 10.1371/journal.ppat.1010467
Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 5, 85–86 (2016).
pubmed: 27175354 pmcid: 4861875 doi: 10.5501/wjv.v5.i2.85
Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).
pubmed: 24025770 pmcid: 3849456 doi: 10.1038/nature12519
Mavigner, M. et al. Simian immunodeficiency virus persistence in cellular and anatomic reservoirs in antiretroviral therapy-suppressed infant rhesus macaques. J. Virol. 92, e00562-18 (2018).
Perelson, A. S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188–191 (1997).
pubmed: 9144290 doi: 10.1038/387188a0
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582–1586 (1996).
pubmed: 8599114 doi: 10.1126/science.271.5255.1582
McGary, C. S. et al. CTLA-4
pubmed: 29045906 pmcid: 5679306 doi: 10.1016/j.immuni.2017.09.018
Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
pubmed: 29203879 pmcid: 5715110 doi: 10.1038/s41598-017-17204-5
Bricker, K. M. et al. Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation. PLoS Pathog. 16, e1008954 (2020).
pubmed: 33104758 pmcid: 7644092 doi: 10.1371/journal.ppat.1008954

Auteurs

Amir Dashti (A)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
ORCID: 0000-0002-4679-7962

Sophia Sukkestad (S)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
ORCID: 0000-0002-0877-0400

Anna M Horner (AM)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Margaret Neja (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Zain Siddiqi (Z)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Chevaughn Waller (C)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Jordan Goldy (J)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Dominique Monroe (D)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
ORCID: 0000-0001-5714-2518

Alice Lin (A)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Nils Schoof (N)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Vidisha Singh (V)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Maud Mavigner (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and Emory University, Atlanta, GA, USA.

Jeffrey D Lifson (JD)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Claire Deleage (C)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
ORCID: 0000-0002-3507-0055

Marina Tuyishime (M)

Department of Surgery, Duke University Medical Center, Durham, NC, USA.

Shane D Falcinelli (SD)

UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
ORCID: 0000-0002-3554-226X

Hannah A D King (HAD)

Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Ruian Ke (R)

Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
ORCID: 0000-0001-5307-8934

Rosemarie D Mason (RD)

Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.

Nancie M Archin (NM)

UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Richard M Dunham (RM)

UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
HIV Drug Discovery, ViiV Healthcare, Research Traingle Park, NC, USA.

Jeffrey T Safrit (JT)

ImmunityBio, Inc., Culver City, CA, USA.

Sherrie Jean (S)

Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
ORCID: 0000-0001-8028-8160

Alan S Perelson (AS)

Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
ORCID: 0000-0002-2455-0002

David M Margolis (DM)

UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
ORCID: 0000-0001-5714-0002

Guido Ferrari (G)

Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Mario Roederer (M)

Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.

Guido Silvestri (G)

Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
ORCID: 0000-0001-6602-2470

Ann Chahroudi (A)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.
Emory National Primate Research Center, Emory University, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.
Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and Emory University, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.
ORCID: 0000-0001-7479-9546

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Maladies de l'animal › Maladies des primates › Maladies des singes › Syndrome d'immunodéficience acquise du singe › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Rétrovirus simiens › Virus de l'immunodéficience simienne › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Latence virale › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système lymphatique › Tissu lymphoïde › Noeuds lymphatiques › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › AZD5582 plus SIV-specific antibodies reduce...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Charge virale › AZD5582 plus SIV-specific antibodies reduce...